Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Shroff

Phase II Study of Nab-Paclitaxel in Refractory Small Bowel Adenocarcinoma and CpG Island Methylator Phenotype (CIMP)-high Colorectal Cancer

Annals of Oncology

English

Acid-Base-Driven Matrix-Assisted Mass Spectrometry for Targeted Metabolomics

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

2009

English

Related publications

CpG Island Methylator Phenotype in Colorectal Cancer

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

1999

English

CpG Island Methylator Phenotype and Prognosis of Colorectal Cancer in Northeast China

BioMed Research International

English

CpG Island Methylator Phenotype Associates With Low-Degree Chromosomal Abnormalities in Colorectal Cancer

Clinical Cancer Research

Cancer Research

Oncology

2008

English

Cyclin D1 Is Frequently Overexpressed in Microsatellite Unstable Colorectal Cancer, Independent of CpG Island Methylator Phenotype

English

Meta-Analysis of the Prognostic Value of CpG Island Methylator Phenotype in Gastric Cancer

British Journal of Surgery

Surgery

2018

English

Polymorphisms in Methyl-Group Metabolism Genes and Risk of Sporadic Colorectal Cancer With Relation to the CpG Island Methylator Phenotype

English

P2.12-02 Phase II Study of Combination of Nab-Paclitaxel and Gemcitabine for Relapsed Small Cell Lung Cancer (SCLC)

Journal of Thoracic Oncology

English

The CpG Island Methylator Phenotype May Confer a Survival Benefit in Patients With Stage II or III Colorectal Carcinomas Receiving Fluoropyrimidine-Based Adjuvant Chemotherapy

English

A Phase I/Ii Study of Weekly Nab-Paclitaxel Plus Cisplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Shroff

Phase II Study of Nab-Paclitaxel in Refractory Small Bowel Adenocarcinoma and CpG Island Methylator Phenotype (CIMP)-high Colorectal Cancer

Acid-Base-Driven Matrix-Assisted Mass Spectrometry for Targeted Metabolomics

Related publications

CpG Island Methylator Phenotype in Colorectal Cancer

CpG Island Methylator Phenotype and Prognosis of Colorectal Cancer in Northeast China

CpG Island Methylator Phenotype Associates With Low-Degree Chromosomal Abnormalities in Colorectal Cancer

Cyclin D1 Is Frequently Overexpressed in Microsatellite Unstable Colorectal Cancer, Independent of CpG Island Methylator Phenotype

Meta-Analysis of the Prognostic Value of CpG Island Methylator Phenotype in Gastric Cancer

Polymorphisms in Methyl-Group Metabolism Genes and Risk of Sporadic Colorectal Cancer With Relation to the CpG Island Methylator Phenotype

P2.12-02 Phase II Study of Combination of Nab-Paclitaxel and Gemcitabine for Relapsed Small Cell Lung Cancer (SCLC)

The CpG Island Methylator Phenotype May Confer a Survival Benefit in Patients With Stage II or III Colorectal Carcinomas Receiving Fluoropyrimidine-Based Adjuvant Chemotherapy

A Phase I/Ii Study of Weekly Nab-Paclitaxel Plus Cisplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer